Melanotan I
Afamelanotide is a melanocortin analogue. An approved implant is not equivalent to an unspecified vial product.
Search names: MT-1, Afamelanotide
Evidence
Catalogue entry · see sources
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: About 30 minutes
Human information in catalogueContext and sources for the statistics reference
Limited basis; the catalogue also mentions 0.8–1.7 hours from an older small human study.
About 30 minutes · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · Melanotan I (MT-1) ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Adverse effects are not fully mapped in this entry. Consult the sources for the specific compound and use.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Find researchPubMed · Melanotan I↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.